On May 28, METiS Pharmaceuticals-P (07666.HK) declined 5.21% in regular trading, trading at HK$16.32 per share, with trading volume of HK$17.99 million.

On the news front, the stock has been in sustained retreat since its listing debut on May 13, when it surged 173% from its IPO price of HK$10.50. As the world's first AI-driven drug delivery company to list on the Hong Kong Stock Exchange, METiS remains in early-stage commercialization, having accumulated approximately RMB 1.5 billion in losses over the past three years with volatile revenue. Additionally, certain international placement shares were not subject to lock-up restrictions, creating persistent profit-taking pressure post-listing.

Although the company recently launched its AiProtein platform and announced a strategic alliance with Deerfield to advance AI-driven protein therapeutics and in-vivo immunotherapy, post-IPO market enthusiasm has continued to cool rapidly, sustaining downward pressure on the share price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)